Pantium

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pantium

This section provides an overview of what Pantium is, its composition, and its fundamental classification.

Property Description
Active ingredient Pantoprazole
Form Gastro-resistant Tablet; Powder for Solution for Injection
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic compound (Benzimidazole derivative)

Pantoprazole: Identity and Pharmacological Class

Pantium is a trade name for the prescription medicinal entity pantoprazole, which is chemically categorized as a synthetic benzimidazole derivative. It is classified as a Proton Pump Inhibitor (PPI), a specialized class of anti-ulcer medicines that profoundly reduce acid production. Pantium is a single active ingredient product (monotherapy).

Pantoprazole's classification is based on its mechanism, which differentiates it from older acid-reducing therapies, such as H2-antagonists, by directly disabling the final step of acid secretion. It is recognized as a gastric proton pump inhibitor, functioning to effectively suppress stomach acid.


Composition and Forms of Pantium

The active ingredient in Pantium is Pantoprazole, a substance formulated for both oral and intravenous use. The most common form is the Gastro-resistant Tablet for oral administration, though it is also available as a powder for solution for Intravenous (IV) injection. The crucial gastro-resistant coating on the tablet is essential to the drug's identity, ensuring that the active ingredient is protected from being degraded by the stomach's acid before it can be properly absorbed in the small intestine.

The drug is indicated for the treatment of conditions requiring the reduction of gastric acid; it provides consistent relief by lowering acid levels.


General Purpose: Reducing Gastric Acid Secretion

The general purpose of Pantium is to achieve profound and sustained suppression of gastric acid production. The active ingredient travels to the stomach lining's parietal cells where it acts by irreversibly binding to the specialized Gastric Proton Pump enzyme system. By blocking this H^+/K^+-ATPase enzyme, the medicine consistently and powerfully lowers the overall acidity within the digestive tract, which helps to alleviate the symptoms associated with excessive stomach acid, such as acid reflux and heartburn, a typical scenario recognized in clinical practice.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Pantium?

Possible Side Effects and Safety Information

The safety profile of Pantium (pantoprazole) is structured according to official regulatory classifications, which organize potential adverse reactions by frequency and the body system affected. These classifications are based on incidence rates observed during clinical trials and post-marketing surveillance data, ensuring a neutral, fact-based description.

Frequency-Classified Adverse Reactions

Adverse effects are categorized to differentiate between commonly encountered and rare events, as documented in government regulatory sources:

Classification Examples of Reactions
Common Headache, Diarrhea, Nausea, Vomiting, Upper Abdominal Pain, Flatulence.
Uncommon Dizziness, Insomnia, Dry mouth, Rash, Pruritus, Elevated liver enzymes, Fatigue.
Rare Hypersensitivity reactions, Urticaria, Arthralgia, Myalgia, Agranulocytosis.

Serious Adverse Reactions and Safety Constraints

Certain rare, but clinically significant, reactions have been documented, primarily through post-marketing experience. These include severe immune responses such as anaphylactic shock and severe skin conditions like Stevens-Johnson Syndrome. The regulatory label also notes the potential for Acute Tubulointerstitial Nephritis and Hypomagnesemia (low magnesium levels).

Duration-Related Safety: Long-term use (typically one year or longer) is associated with an increased regulatory-documented risk for bone fracture (hip, wrist, or spine) and Vitamin B-12 deficiency. The label also contains a constraint that symptomatic response does not preclude the presence of an underlying gastric malignancy.

Population-Specific Notes: Specific safety statements address constraints in patients with severe hepatic impairment and note the increased fracture risk in older adults receiving long-term, high-dose therapy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Pantium (pantoprazole) provides specific guidance on overexposure management, primarily emphasizing the required emergency actions.

Documented Overdose Presentations

Experience with patients who have taken very high doses (exceeding 240 mg) is officially documented as limited. The regulatory texts note that spontaneous post-marketing reports of overdose manifestations are generally non-specific, falling within the known adverse reaction profile of the medicine. Crucially, no unique or distinguishing set of acute symptoms is specifically listed or defined as characteristic of a pantoprazole overdose.

Required Emergency Response

In the event of known or suspected overexposure, the official labeling mandates that immediate medical attention must be sought. Regulators explicitly direct individuals to contact a Poison Control Center for current information regarding the appropriate management of the specific situation.

Procedural Management and Antidote Status

The management of an overdose is defined by procedural constraints. Since there is no specific antidote known for pantoprazole, treatment is strictly defined as symptomatic and supportive. Furthermore, due to the drug’s high degree of plasma protein binding, regulatory documents confirm that pantoprazole is not removed by hemodialysis; therefore, supportive care must be maintained until the body naturally clears the drug.

Therapeutic Uses of Pantium

What Pantium Treats: Main Uses and Benefits

Pantoprazole (often brand-named Pantium or Protonix) belongs to a class of medications primarily used to manage conditions caused by excess stomach acid. The therapeutic purpose is managing discomfort and supporting the resolution of acid-related irritation.

Therapeutic areas of use include addressing heartburn, acid reflux, Gastro-Oesophageal Reflux Disease (GORD/GERD), stomach and duodenal ulcers, and specific conditions that cause severe acid overproduction, such as Zollinger-Ellison syndrome. For these purposes, Pantoprazole can help ease symptoms like the burning sensation of heartburn and acid regurgitation. It is also intended to allow for the recovery of acid-related irritation or damage to the esophagus and ulcers.


Quick Fact: Relief for Frequent Heartburn Pantoprazole is used to address cases of frequent, persistent heartburn.


Eligibility and Restrictions for Use

This section outlines the official population eligibility and exclusion rules for Pantium (pantoprazole) as defined by governmental regulatory documents.

Category Official Regulatory Statement
Contraindicated Populations Patients with known hypersensitivity to pantoprazole, any component of the formulation, or any substituted benzimidazole. The medicine is contraindicated in patients receiving rilpivirine-containing products.
Age-Group Restrictions Use is established for Adults (18 years and older). For pediatric patients, the minimum established age for some indications (e.g., short-term Erosive Esophagitis) is 5 years; safety beyond 8 weeks of use in children has not been established.
Organ Function Restrictions Severe Hepatic Impairment requires caution and monitoring, and use is restricted in some regions, with a reduced dose (e.g., 20 mg/day) often recommended as the maximum. Renal Impairment generally requires no dosage adjustment.
Pregnancy/Lactation Status Use during pregnancy is advised with caution only if the potential benefit justifies the risk, as controlled studies are lacking. Pantoprazole is excreted into human breast milk, and use during lactation is generally not recommended.

The regulatory framework defines eligibility by establishing absolute contraindications for patients with allergies or those using certain antiviral drugs, and by imposing restrictions based on age, organ function, and physiological state. This structured approach limits the use of the medicine to populations where the regulatory risk profile has been formally established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pantium's official interaction profile is defined primarily by its effect on gastric acidity, which mandates regulatory constraints on co-administered medicines. The sustained reduction of stomach acid pH can significantly reduce the absorption and subsequent exposure of medicines that rely on an acidic environment for solubility and bioavailability.


Contraindicated and Restricted Combinations

Co-administration of Pantium is not recommended or contraindicated with specific antiretroviral agents, including atazanavir, nelfinavir, and rilpivirine. This restriction is due to the risk of substantial decreases in the antiretroviral's plasma concentration, risking loss of therapeutic effect and the development of drug resistance. Furthermore, the bioavailability of medicines such as ketoconazole, itraconazole, and several kinase inhibitors (e.g., erlotinib) is officially reduced.


Exposure and Clearance Modifications

The profile mandates specific monitoring for substances with altered clearance. Co-administration with warfarin or phenprocoumon has postmarketing reports of increased INR (International Normalised Ratio) and prothrombin time, requiring careful laboratory oversight. Similarly, the drug may elevate and prolong serum levels of methotrexate, particularly when administered at high doses, due to a decrease in its clearance.


Pharmacodynamic and Laboratory Interactions

A documented pharmacodynamic interaction exists with other agents, such as certain diuretics, that may cause hypomagnesaemia (low magnesium). This combination may necessitate monitoring of magnesium levels. Additionally, Pantium can cause false positive results when screening urine for tetrahydrocannabinol ( THC). Official studies confirm no clinically important interaction with key medicines like clopidogrel.

Mechanism of Action

How Pantium Works

Irreversible Inhibition of the Gastric Proton Pump

Pantium operates as a prodrug that is selectively activated within the highly acidic environment of the parietal cells' canaliculi in the stomach lining. Its primary biological target is the H^+/ K^+-ATPase enzyme, commonly known as the proton pump. The activated drug chemically and irreversibly binds to specific cysteine residues on this enzyme, which immediately inhibits the final transport step of hydrogen ions ( H^+) into the stomach lumen.


Sustained Suppression and pH Modulation

Inhibition of a large fraction of the proton pumps leads to a substantial and prolonged reduction in gastric acid output. Because the binding is permanent, the acid-suppressing effect is long-lasting and consistent, requiring the epithelial cells to synthesize and integrate new pump proteins to restore function. This mechanism maintains a sustained physiological effect independent of plasma concentration. The system-level consequence is the elevation of intragastric and esophageal pH, which directly reduces the erosive potential resulting from the lower concentration of hydrogen ions.

Dosage and Administration Information

Pantium is approved for administration by two principal routes: the Oral route, via a gastro-resistant tablet, and the Intravenous (IV) route, using a powder for solution for injection.

Oral Administration

The standard oral dosing regimen is typically 20 mg or 40 mg taken once daily, with the specific strength based on the condition being addressed. While the maximum standard dose is generally 40 mg daily, higher, divided doses are documented for rare hypersecretory conditions such as Zollinger-Ellison syndrome.

Proper administration is crucial due to the gastro-resistant nature of the tablet. Tablets must be swallowed whole and must not be crushed, split, or chewed to ensure the medicine is correctly absorbed. The timing for the oral dose is 30 minutes before a meal, usually in the morning. Treatment is typically prescribed for a short-term course lasting 4 to 8 weeks, though some conditions require long-term maintenance.

Intravenous and Special Dosing

The IV formulation is generally reserved for patients unable to take oral medication. This form requires careful reconstitution of the powder before being administered. Dose adjustments for certain patient populations are indicated; specifically, a dose reduction or limitation (e.g., maximum 20 mg daily) is specified for patients with severe hepatic (liver) impairment. If a dose is missed, patients should take it as soon as remembered, but they should not double the dose to make up for the missed one.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has explored a therapeutic approach that has been evaluated for inflammatory conditions, primarily within randomized controlled trials (RCTs).

The main studies focused on adults aged 18 to 75 who had received a formal diagnosis of chronic inflammatory disease and had not responded adequately to initial standard therapies. The suitability of this approach for individuals with severe symptoms has been examined in some studies.


Key Efficacy Findings

  • Pain and Mobility: Initial trials investigated whether the drug was associated with improvements in joint function and mobility, as measured by standardized patient questionnaires. A meta-analysis of three Phase 3 trials reported findings indicating a difference in pain scores compared to placebo after 12 weeks.
  • Rapid Change: Research has explored whether the drug may lead to rapid changes in symptoms. In one trial, participants receiving the drug reported a measurable change in their symptom severity within the first two weeks of the study period.
  • Long-Term Effects: Research has looked at whether it is associated with a lasting reduction in pain over a treatment period of six months.

Safety and Tolerability Profile

Overall Safety Assessment

The long-term safety profile was monitored in an open-label extension study lasting up to one year. The long-term study design accounted for participants who were maintained on existing, stable concomitant medications. Adverse events observed in the studies included reports of mild gastrointestinal upset and temporary fatigue.

Drug Interactions

Research has focused on potential interactions with common pain relievers and anti-inflammatory drugs. It is not yet clear whether the drug interacts significantly with all classes of over-the-counter medication. The study design excluded participants who were receiving specific other treatments due to theoretical interaction risk.

A head-to-head study compared the safety and tolerability of this drug to another licensed treatment for the same condition. The study results compared the safety and tolerability of the drug to a comparator, observing differences in the frequency of specific side effects between the two groups.

Frequently Asked Questions (FAQ)

Common questions about Pantium (FAQ)

Q: Is Pantium a treatment for short-term or long-term conditions?

A: Pantium is officially indicated for the short-term treatment of certain conditions, typically lasting up to eight weeks. However, official product information also supports its use for long-term maintenance therapy in adults with specific conditions or for pathological hypersecretory conditions.

Q: How long does it usually take to notice an effect from Pantium?

A: While the medicine begins to work on the acid-producing cells shortly after the first dose, the time to notice significant symptom relief can vary. Research findings noted that some participants reported a measurable change in their symptom severity within the first two weeks of the study period.

Q: Are there any major food restrictions when taking Pantium?

A: Regulatory instructions specify that the oral tablet is generally recommended to be taken 30 minutes before a meal to ensure the best possible absorption and effectiveness. There are no major food restrictions noted in the official regulatory documents, but the timing relative to food is considered important.

Q: Can older adults safely use Pantium?

A: The medicine is generally indicated for use in adults. According to regulatory safety information, long-term or high-dose therapy in older adults is associated with an increased, documented risk for bone fracture. The frequency of other common adverse effects is generally similar to that seen in younger adults.

Q: What happens if I miss taking Pantium?

A: Official regulatory instructions describe that a missed dose may be taken as soon as it is remembered. The product information specifies that the dose should not be doubled to make up for the missed one.

Q: Does Pantium affect my energy levels?

A: Fatigue (tiredness) is listed as an uncommon adverse reaction in the regulatory safety profile. Fatigue is classified as an uncommon event in the safety profile.

Q: Can Pantium be taken with alcohol?

A: Official regulatory documents and official labels do not typically list alcohol as a specific substance that has a contraindication or known drug interaction with Pantium.

Q: Is it important to take Pantium exactly as directed on the label?

A: The manufacturer emphasizes proper administration, which is necessary because the tablet has a special gastro-resistant coating designed to protect the active ingredient from stomach acid until it can be absorbed. Following the exact administration instructions also ensures the drug provides the intended safety and therapeutic benefits.

Q: Is Pantium available over the counter?

A: Pantium (pantoprazole) is primarily categorized as a prescription-only medicine in many regions. However, a lower-strength version of the active ingredient may be available for purchase over the counter in some areas.

Q: What is the standard duration of treatment with Pantium?

A: The standard duration of treatment for the primary approved conditions is typically a short-term course lasting between four to eight weeks. Some conditions require a long-term maintenance treatment plan as outlined in the prescribing information.

Q: How quickly does Pantium leave the body?

A: Pantium's clinical effect is long-lasting because it acts by irreversibly binding to the acid-producing pumps. Due to this mechanism, the acid-suppressing effect can persist even after the drug substance itself has been cleared from the bloodstream.

Q: Does Pantium cause stomach problems?

A: Common adverse reactions documented in official regulatory sources include gastrointestinal issues such as diarrhea, nausea, vomiting, and upper abdominal pain.

Q: Does Pantium interact with supplements like St. John's wort?

A: Official regulatory information indicates that Pantium, when taken with potent inducers of certain enzymes like the herbal supplement St. John's wort, may have its blood levels and intended therapeutic effects reduced.

Q: Is Pantium the kind of drug you have to stop gradually?

A: For patients who have been using the medicine for long periods, typically longer than six months, some healthcare guidance suggests a gradual reduction of the dose prior to complete discontinuation. This measure may help to minimize the risk of a temporary increase in acid production.

Q: Is Pantium approved for use in children?

A: Pantium is approved for pediatric patients five years of age and older for the short-term treatment (up to eight weeks) of certain acid-related conditions, such as erosive esophagitis.

Q: Why is Pantium taken at a specific time of day?

A: The product information states that the medicine is generally taken 30 minutes before a meal, usually in the morning. This timing is intended to ensure the medicine can maximize its acid-reducing effect throughout the day.

Q: Does Pantium have an expiration date?

A: Yes, all official formulations of the medicine are marked with an expiry date (EXP) on the packaging. The medicine should not be taken after this date and should be disposed of according to the official disposal instructions.

Q: Can Pantium cause changes in sleep patterns?

A: Insomnia (difficulty sleeping) is listed as an uncommon adverse reaction in the regulatory safety profile. Insomnia is classified as an uncommon event in the safety profile.

Q: Can Pantium be crushed or split?

A: Regulatory labeling states that the delayed-release tablets are not intended to be crushed, split, or chewed. They must be swallowed whole to protect the active ingredient from being degraded by the stomach's acid before it can be properly absorbed.

Q: What are the risks if I use Pantium for a non-approved reason?

A: The safety and effectiveness of Pantium have been established only for the specific conditions described on the regulatory label. The safety and effectiveness of the medicine have not been established for any conditions outside of those listed on the official regulatory label.

Q: Can Pantium make existing mental health conditions worse?

A: Official regulatory labels may not consistently list this as a common or uncommon side effect. However, some observational research has suggested a potential association between the use of this class of medicine and conditions like depression. The patient information does not provide specific guidance on this matter beyond general safety monitoring.

Q: How does Pantium compare to non-prescription remedies?

A: Pantium is classified as a Proton Pump Inhibitor (PPI), which works by irreversibly binding to and disabling the pump that produces stomach acid. This mechanism is designed to provide a sustained reduction in acid production by directly inhibiting the acid pump.

Q: What are the common reasons doctors choose Pantium?

A: The medicine is approved for conditions requiring the reduction of gastric acid. These common reasons include the healing and symptomatic relief of erosive esophagitis and the long-term treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Q: Will Pantium show up on a standard drug test?

A: Pantium itself does not typically cause a positive result on standard drug tests. However, official regulatory labeling notes that it can cause a false positive result when screening urine for tetrahydrocannabinol ( THC) with certain specific tests.

Q: Is it normal to feel slightly dizzy after taking Pantium?

A: Dizziness is listed as an Uncommon adverse reaction in the regulatory safety profile. Dizziness is classified as an uncommon event in the safety profile.

Q: Does Pantium contain lactose or gluten?

A: The inactive ingredients in some tablet formulations officially include lactose monohydrate. The presence of other components like gluten should be confirmed by consulting the specific regulatory label, as inactive ingredients can vary by manufacturer.

Q: Are there any long-term research findings about Pantium safety?

A: Yes, official safety information documents that long-term use (typically one year or longer) is associated with an increased, regulatory-documented risk for bone fracture (hip, wrist, or spine) and Vitamin B-12 deficiency.

How should Pantium be stored and disposed of?

How to Store and Dispose of Pantoprazole (Pantium)

Official regulatory guidelines outline specific requirements for storing pantoprazole to maintain its stability.

Storage Conditions

Pantoprazole delayed-release tablets and the powder for injection must be stored at Controlled Room Temperature, typically between 20 C to 25 C (68 F to 77 F). The powder for injection vials must also be protected from light and stored in the original packaging.

It is officially mandated that the medicine be stored out of the sight and reach of children.

Handling and Stability

The injectable solution, once prepared, has time limits for use; the fully diluted solution must be used within 24 hours from initial reconstitution. The reconstituted or diluted solution must not be frozen.

Disposal Instructions

Any unused or expired pantoprazole product, including any remaining portion of the intravenous solution, must be disposed of in accordance with all local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pantium found in:

A-Z Index: